| 前收市價 | 0.9100 |
| 開市 | 1.1400 |
| 買盤 | 1.2100 |
| 賣出價 | 1.2800 |
| 拍板 | 125.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 1.1400 - 1.4200 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 6k |
BenzingaMerck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab) compared to Keytruda alone as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV). Also Read: Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook. Data from a pre-planned analysis showed tha
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
ZacksHere's Why Merck (MRK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
